drugset / Trial / NCT00156156

Study of Asoprisnil in the Treatment of Uterine Fibroids.

NCT00156156

Phase 3 Completed 149 enrolled Abbott
Non-randomizedParallel-groupSingle-blindTreatment

Summary

The objective of this study is to determine the long-term safety of asoprisnil in women with abnormal uterine bleeding associated with uterine fibroids.

Timeline

Start
2004-11
Primary completion
2007-02
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Asoprisnil Other / unclassified 10 mg Oral
Subject Asoprisnil Other / unclassified 25 mg Oral